Balboa Bioconsulting, INC.
Dr. Gerald Kolaja established Balboa BioConsulting in 2008. He is a ACVP board certified veterinary pathologist. The company provides histopathology and safety assessment expertise to biotechnology and pharmaceutical companies. Dr. Kolaja has over 30 years experience in pathology and pharmaceutical development. Moving compounds from discovery to development and assisting in strategies to study mechanisms of toxicity are strengths of the company. Located in San Diego, the company primarily focuses on West Coast clients, however, clients are located on the East Coast as well as international locations.
Dr. Viveash has a distinguished career spanning three decades of global experience in biologics and small molecule development, including the commercialization of numerous products including anti-inflammatory, oncology, and metabolic disorders. Prior to joining Balboa BioConsulting, Dr. Viveash held vice president positions at Orexigen, Amylin, Amgen, Immunex and Pharmacia & Upjohn. Areas of responsibility included regulatory affairs, clinical safety and quality assurance. Dr. Viveash contributed to the successful development of a number of products including most recently Contrave, Bydureon, Byetta, Kepivance, Vectibix, Aranesp, Neulasta and Enbrel. Dr. Viveash played a significant role as a company representative in a number of FDA advisory committees relating to product approval and product safety assessment. Dr. Viveash received her degree in Pharmacy from The School of Pharmacy, London University, her medical degree from University College Medical School, London University and qualified as a member of the Royal College of Physicians UK.